Today: 12 June 2026
Browse Category

NYSE:LLY 16 August 2025 - 6 October 2025

Shutdown Drags On But Wall Street Hits Records – Here’s What’s Driving Markets

Shutdown Drags On But Wall Street Hits Records – Here’s What’s Driving Markets

The S&P 500 and Dow closed at record highs despite a second week of U.S. government shutdown, while the Nasdaq lagged as tech shares wavered. Key economic data releases were delayed, forcing traders to rely on private surveys showing continued labor market weakness. Markets expect the Federal Reserve to cut rates in October. Japan’s Nikkei hit a record after a pro-stimulus leader’s election, and gold reached $3,944 an ounce.
6 October 2025
····
Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

Bitcoin surged past $125,000 to a record high as investors poured in. Elon Musk’s xAI and OpenAI filed lawsuits against each other, with OpenAI calling Musk’s claims “harassment.” Tesla teased an Oct. 7 event for a cheaper electric car. Firefly Aerospace agreed to buy defense firm SciTec for $855 million to expand military space work.
6 October 2025
··········
U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

All three major U.S. indexes closed at record highs on Oct. 1, with the S&P 500 topping 6,700 for the first time. ADP reported U.S. private payrolls fell by 32,000 in September, fueling bets on two Fed rate cuts by year-end. The 10-year Treasury yield dropped to 4.10%, gold hit a record near $3,895, and healthcare stocks surged after a Trump–Pfizer price deal. Lithium Americas soared 23% after a U.S. government investment.
2 October 2025
······
Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

U.S. stocks closed at record highs despite a partial government shutdown, with the S&P 500 up 0.34% to 6,711.20 and the Dow rising 0.09% to 46,441.10. Health-care shares jumped after Pfizer and the White House struck a drug price deal, sending Biogen up 10.9%. The ADP report showed private-sector jobs fell by 32,000 in September, but investors bet on Fed rate cuts.
1 October 2025
·····
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

The Federal Reserve cut rates by 25 basis points to 4.00–4.25% in mid-September, citing slowing growth as inflation remains above target. The S&P 500 is up about 13% in 2025, but strategists warn valuations are high. Compass agreed to buy Anywhere for $4.2 billion in stock, sending Anywhere shares up nearly 49%. The U.S. implemented a new auto trade pact with the EU, lowering tariffs to 15% as of August 1.
28 September 2025
·············
Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Nvidia will invest up to $100 billion to build 10 gigawatts of AI data centers for OpenAI, with the first 1 GW due by late 2026. The US cybersecurity agency issued an emergency directive after hackers breached at least one federal agency via Cisco firewall flaws, affecting hundreds of devices. The FDA approved Eli Lilly’s new breast cancer drug Inluriyo. The SEC loosened ETF rules, opening the door for new crypto ETFs.
28 September 2025
·········
Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

The Nasdaq snapped a three-week win streak despite a Friday rebound, closing at 22,484, down 0.6% for the week. Trump announced new tariffs on trucks, pharma, and furniture, sending Paccar up 5.2% and RH down 4%. Nvidia signaled a $100 billion OpenAI investment, fueling a semiconductor rally. Core inflation matched forecasts at 2.7% year-on-year in August.
27 September 2025
··········
Wall Street Rebound: Fed Relief, Tariff Twists & Tech Surprises (NYSE Highlights Sept 26–27, 2025)

Wall Street Rebound: Fed Relief, Tariff Twists & Tech Surprises (NYSE Highlights Sept 26–27, 2025)

U.S. stocks rebounded Friday, with the Dow up 0.7%, S&P 500 0.6%, and Nasdaq 0.4%, but all three still posted weekly losses. August core PCE inflation matched forecasts at 0.2%. The Fed cut rates for the first time since December and signaled more cuts possible. Trump announced new tariffs on trucks, drugs, and furniture, boosting shares of Paccar and Eli Lilly.
27 September 2025
······
Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

U.S. inflation matched forecasts in August, with PCE up 0.3% from July and 2.7% year-on-year. Stocks rebounded, the S&P 500 and Dow rising about 0.5% by early afternoon. The White House announced new tariffs on drug imports, trucks, and furniture, effective Oct. 1. Treasury yields slipped, with the 10-year near 4.18% after the data release.
26 September 2025
·······
Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Researchers used AI to design the first viruses from scratch, creating bacteriophages that killed drug-resistant bacteria. Scientists solved why smoking affects ulcerative colitis and Crohn’s disease differently, linking it to mouth bacteria. New Alzheimer’s drugs modestly slowed disease in early stages. Wildfire smoke could kill 70,000 Americans annually by 2050, Stanford researchers warned.
20 September 2025
·····
Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Eli Lilly’s oral weight-loss drug orforglipron led to about 12% average body weight loss over 72 weeks in a large trial, but results plateaued after a year. The pill’s effect was less than leading injectables like Wegovy and Zepbound. Side effects were mostly mild gastrointestinal issues; no serious liver or thyroid problems were reported. About 10% of patients on the highest dose dropped out due to side effects.
17 September 2025
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly will invest $5 billion to build a 200,000-square-foot drug manufacturing plant in Goochland County, Virginia, creating 650 permanent jobs and 1,800 construction jobs. The facility will produce active pharmaceutical ingredients for cancer and autoimmune treatments. The project is part of Lilly’s $27 billion U.S. expansion plan. Virginia approved over $10 million in incentives to secure the site.
16 September 2025
·······
Game-Changing AI Breakthroughs, Big Tech Surprises & Global AI Showdowns (Sept 9–10, 2025)

Game-Changing AI Breakthroughs, Big Tech Surprises & Global AI Showdowns (Sept 9–10, 2025)

Researchers at Stony Brook University unveiled an AI tool that detected signs of consciousness in coma patients up to eight days before standard exams. The system analyzed subtle facial muscle movements invisible to doctors. In a study of 37 patients, the AI identified awareness earlier than bedside neurological tests. Up to 25% of patients labeled “unresponsive” may actually be conscious, researchers said.
10 September 2025
·····
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

The U.S. administration fired CDC Director Dr. Susan Monarez after she resisted Health Secretary Robert F. Kennedy Jr.’s directives; four senior CDC officials resigned in protest, citing risks to young Americans and pregnant women. U.S. regulators approved updated COVID-19 vaccines for fall, but limited routine access to adults 65+ and high-risk groups, excluding healthy under-65s.
28 August 2025
····
Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Eli Lilly’s oral weight-loss drug orforglipron cut body weight by up to 10.5% in a Phase 3 trial for obese diabetics, with all doses meeting primary endpoints over 72 weeks. The FDA granted full approval to Precigen’s Papzimeos, the first gene therapy for adult recurrent respiratory papillomatosis. AbbVie agreed to acquire a psychedelic-based depression drug from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
27 August 2025
·····
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······
Tariff Tsunami, Tech Tumble & Peace Talk Buzz – Global Business Roundup (Aug 19–20, 2025)

Tariff Tsunami, Tech Tumble & Peace Talk Buzz – Global Business Roundup (Aug 19–20, 2025)

Nvidia shares fell sharply on August 19, 2025, as a tech selloff pulled the Nasdaq down 1.5%. President Trump met Ukraine’s president and pledged U.S. support for Ukraine’s security in any peace deal. The U.S. Commerce Department expanded 232 tariffs to 407 new categories, affecting over $200 billion in imports. New Zealand’s central bank cut rates to 3.00%, sending the kiwi dollar to $0.584.
20 August 2025
········
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········
AI Stock Frenzy: Big Tech Bets, Billion-Dollar Deals & Market Shifts (Aug 15–16, 2025)

AI Stock Frenzy: Big Tech Bets, Billion-Dollar Deals & Market Shifts (Aug 15–16, 2025)

Bridgewater more than doubled its Nvidia stake in Q2 2025, while Tiger Global bought millions more Amazon shares and raised bets on Alphabet, Nvidia, Microsoft, and Meta. On August 14, Oracle and Google Cloud announced a partnership to offer Gemini AI models via Oracle Cloud. Insiders said OpenAI is in talks to sell $6 billion in shares at a $500 billion valuation. Tesla shelved its Dojo AI supercomputer and will rely on Nvidia GPUs.
16 August 2025
··········
1 … 10 11 12 13

Stock Market Today

  • Oracle Shares Fall on $20 Billion Fundraising; Navan, Anterix, Driven Brands Beat Estimates
    June 12, 2026, 7:12 AM EDT. Oracle Corp (ORCL) shares dropped 8.5% after announcing a $20 billion equity and debt raise to fund AI development, alongside reporting annual negative free cash flow. Meanwhile, Navan Inc (NAVN) surged 8.4% after beating first-quarter fiscal 2027 adjusted earnings estimates with $0.08 per share compared to a loss of $0.01. Anterix Inc (ATEX) shares jumped 25.7% after posting a narrower adjusted loss than expected for Q4 fiscal 2026. Driven Brands Holdings Inc (DRVN) rose 2.1% following better-than-expected adjusted earnings per share of $0.30. These moves highlight shifting investor focus amid the ongoing AI expansion beyond major infrastructure players.

Latest articles

OpenAI and Anthropic IPO talk grows as SpaceX sticks to $75 billion mark

OpenAI and Anthropic IPO talk grows as SpaceX sticks to $75 billion mark

12 June 2026
SpaceX’s $75 billion IPO sets a $1.77 trillion valuation benchmark as it prepares to begin Nasdaq trading Friday, more than doubling Saudi Aramco’s 2019 record and making SpaceX one of the most valuable U.S.-listed companies, with the first sessions expected to influence how investors and bankers approach upcoming OpenAI and Anthropic IPOs.
Go toTop